Novartis shares rise after multiple sclerosis pill hits trial goals
Novartis shares rose 4.5% in European midday trading Tuesday after the drugmaker reported positive results from two late-stage multiple sclerosis trials, saying its new pill reduced flare-ups.
By Adria CalatayudNovartis shares rose after the drugmaker reported positive results from two late-stage trials in the most common form of multiple sclerosis, saying its new pill helped patients experience fewer flare-ups.Shares in Novartis were up 4.5% in European midday trading Tuesday, taking th…